KPV

KPV is the C-terminal tripeptide (Lys-Pro-Val) of α-melanocyte-stimulating hormone (α-MSH) and retains much of the parent hormone's anti-inflammatory activity while lacking its pigmentary effect. In preclinical models its actions appear largely receptor-independent: in intestinal epithelial and immune cells it is taken up via the di/tripeptide transporter PepT1, and intracellularly it interferes with pro-inflammatory signalling by inhibiting NF-κB and MAP-kinase pathways, lowering cytokine production. Because PepT1 is up-regulated in inflamed gut tissue, uptake is thought to concentrate where inflammation is greatest. Its small size makes it comparatively stable and amenable to oral or targeted (e.g. nanoparticle) delivery in experimental work. This mechanistic picture is drawn almost entirely from cell and rodent studies.

KPV has a coherent preclinical anti-inflammatory story but limited human evidence. Dalmasso et al. (2008) showed PepT1-mediated KPV uptake reduces inflammation and attenuates disease in mouse DSS- and TNBS-colitis models. Viennois et al. (2016) extended this, reporting that KPV delivered via PepT1 reduced tumour burden in a murine model of colitis-associated cancer. These are animal and cell data; robust controlled human trials are lacking, and KPV is not an approved drug. Reported findings should be read as promising preclinical signals, not established clinical benefit.

Educational overview only — no dosing instructions in the public hub.

Efficacy evidence is preclinical, and long-term human safety is unknown; the anti-inflammatory activity seen in animals has not been confirmed to translate into a favourable human benefit-risk profile. For material sold as 'research use only', unverified sourcing and purity are the dominant practical concerns, and formulation/route assumptions from experimental delivery systems do not carry over to unsupervised use.

A third-party CoA covering identity, purity (HPLC) and mass confirmation (MS) is the minimum verification. As a tripeptide it is relatively simple to synthesise, but confirming the correct Lys-Pro-Val sequence and stated purity still requires proper analytics rather than relying on a label.

Research-use-only in most jurisdictions; not approved for human use by the FDA or EMA. It is an α-MSH-derived tripeptide studied preclinically, not an authorised medicine.